Renal denervation has taken the spotlight at many recent clinical meetings for those in the vascular therapy field. The procedure uses a catheter-based probe inserted into the renal artery that emits high-frequency energy to deactivate nerves in the renal artery that are linked to high blood pressure. The first human randomized controlled trial of therapeutic renal denervation was completed in March 2011 by a group of interventional radiologists and concluded that renal denervation could be effective for reducing and controlling resistant hypertension.
In January 2012, the first renal denervation procedure performed in Canada took place at the Peter Munk Cardiac Centre. See video of the procedure below.
Since the time of the first study, several others have been planned and undertaken, and new devices have been announced. Read more about some of these here:
- One-Year Results from the Symplicity HTN-2 Randomized Controlled Trial Studying Renal Denervation Published
- Vessix Vascular to Present V2 Renal Denervation System for Hypertension at TRenD Workshop 2012
- St. Jude Medical Announces First Patient Enrollment in EnligHTN II Renal Denervation Study
- Boston Scientific Buys Vessix for Blood Pressure Device for Renal Denervation